TPEX
24.5.2021 11:02:13 CEST | Business Wire | Press release
The Taipei Exchange, TPEx, launched a dedicated segment for sustainable bonds, celebrating on May 18 with the debut of three social bond listings. The segment marks a milestone for Taiwan’s socially responsible investment and is in accordance with a plan announced by the Taiwanese government’s Financial Supervisory Commission (FSC). The commission’s plan, named the Green Finance Action Plan 2.0, was announced in August 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005043/en/
TPEx Chairman Philip Chen said in a statement announcing the new segment, “After accomplishing the mechanism regarding social bonds, the last piece of the puzzle, TPEx has integrated the regulations of Green Bonds, Sustainability Bonds, and Social Bonds and launched this segment exclusively for ESG concept bonds.” Chen went on to highlight TPEx’s market acclaim for launching Green Bond and Sustainability Bond operational directions in 2017 and 2020 respectively, which were in line with the ICMA’s GBP and SBG. The total outstanding amount of listed sustainable bonds has steadily grown, exceeding NT$207bn (US$7bn), according to Chen.
The first batch of three social bonds listed on TPEx is primarily funding socioeconomic advancement projects related to the global COVID-19 pandemic, projects such as increasing access to loans, providing job opportunities and raising the availability of affordable housing.
FSC Chairman Dr. Tien-Mu Huang said, “FSC fully supports financial innovation and product diversity. The Sustainable Bond Segment at TPEx provides the market with a clearer, more complete and consistent regulatory mechanism, facilitating easier compliance for issuers. This subsequently serves to direct funds to eco-friendly and socially beneficial projects, helping achieve the goals of Green Finance Action Plan 2.0 tremendously.” Mrs. Tania Berchem from the Luxemburg Trade and Investment Office in Taipei, Mr. Nicholas Pfaff from ICMA, and Mr. Sean Kidney from CBI all sent their congratulatory messages to TPEx for the dedicated segment.
Meanwhile, TPEx has modernized its sustainable bonds website (https://www.tpex.org.tw/web/bond/sustainability/index.php?l=en-us ), improving all relevant information for clarity and accessibility. The updated website is bilingual, and key features have been added which include issuance status and bond framework information, assessment opinions from external reviewers, market reports, and access to current sustainability studies and research reports. Speaking of the new website, Chen added, “In facilitating responsible investing, we hope to offer a full array of information to enhance transparency while simultaneously raising investors’ social awareness.”
About the Taipei Exchange
Established in 1994, the Taipei Exchange is a member of the World Federation of Exchanges. The exchange has grown with a vision of sustainability to meet the diverse needs of issuers and investors, and has long been dedicated to fostering emerging, high-tech and creative industries by providing a viable channel for raising capital. The exchange has also established a fast-growing bond market. For more information, visit: https://www.tpex.org.tw/web/index.php?l=en-us
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom